Pharmafile Logo

Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act

December 6, 2024 |  

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations.

IRA payer survey results

How are payers responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act? Explore our findings.

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, we employed our RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations. This included national and regional Managed Care Organizations (MCOs), Pharmacy Directors (PDs), Integrated Delivery Networks (IDNs), and Pharmacy Benefit Managers (PBMs), representing a total of 96 million MCO/IDN lives and 115 million PBM lives.

Our findings reveal critical insights into how payers are adapting to the recent release of MFPs for key pharmaceutical products under the IRA. For example:

💡 Payers view the MFPs for the diabetes and cardiovascular products most favorably and plan to leverage them in upcoming commercial rebate negotiations. However, payers see unmet needs for further discounts for the immunology and oncology products.

💡 Payers are divided on preferring MFP over non-MFP products due to the potential for non-MFP products to offer more aggressive rebates or better clinical benefits.

View the graphic above for further details.

This is just the first glimpse into a larger narrative. Follow us on LinkedIn to view Part Two of our findings and stay tuned for our interim report within the coming weeks. This report will offer further detail as to how MFPs could reshape both payer strategies and the healthcare market.

You can find out more about our RPR stakeholder engagement platform and global network of 3500+ vetted stakeholders online or contact solutions@genesisrg.com if you have questions or would like to request a copy of the report in advance.

Follow us on LinkedIn>>

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Genesis Research Acquires Market Access Transformation

Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),...

GHO Capital Acquires Genesis Research

GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes...

Genesis Research: What is EVID AI?

Genesis Research Announces Significant Enhancements to EVID AI, the World's Largest AI-Enabled Healthcare Literature Database for Faster, More Efficient Searches